An observational study in Von Willebrand Diseases, sponsored by University of Washington. Recruiting at 11 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by University of Washington · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in von Willebrand Diseases with a site in United States — 11 open to participants now, 12 under way, 2 of them phase 3. von Willebrand Diseases · United States.
Among the 38 studies in von Willebrand Diseases with a site in United States, this one is the 11th largest by planned enrollment of the 16 observational ones that give a count, is one of 5 that started in 2019, is one of 16 observational ones, reaches primary completion later than 1 of the 11 other live ones, and was the 23rd registered.
96 studies on the registry are indexed under von Willebrand Diseases; 25 are open to participants now.
Browse von Willebrand Diseases studies →11 of the 38 studies in von Willebrand Diseases with a site in United States are open now. Recruiting first, the newest first:
Alnylam Pharmaceuticals · Sites in United States, Germany, Netherlands and 3 more countries
Ages 16–45 · Women only
Vega Therapeutics, Inc · Sites in United States, Australia, Austria and 7 more countries
Ages 12–75
Oregon Health and Science University · Sites in United States
Ages 10–24 · Women only
Hemab ApS · Sites in United States, Australia, United Kingdom
Ages 16–69
Takeda · Sites in United States, France, Ireland and 3 more countries
Ages up to 17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 von Willebrand Diseases studies recruiting now, 15 (65%) set no upper age limit and 8 (35%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 11 · Phase 4 1
First in 2001; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is close to the median of 110 across 50 observational studies indexed under von Willebrand Diseases.
Median enrollment 30 across the 22 interventional studies, 127 across the 16 observational. Of the 25 that completed or were terminated, 13 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 38 have an industry lead sponsor. The 10 most frequent:
University of Washington is the lead sponsor of 1,435 studies on the registry; 225 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 137 (87%) have results posted.
University of Washington has 1 study filed under von Willebrand Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in von Willebrand Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06610201Hemab ApSA Study of Bleeding and Treatment in Participants With Von Willebrand Disease | 2026-12 |
| NCT04146376University of WashingtonVon Willebrand Factor in Pregnancy (VIP) Study | 2026-12 |
| NCT07575308Alnylam PharmaceuticalsHMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB | 2027-06-30 |
| NCT06754852Hemab ApSA Study Assessing HMB-002 in Participants With Von Willebrand Disease | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies in von Willebrand Diseases with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding.
This is a prospective, open-label, cohort study in women with VWD using Wilate VWF replacement therapy to maintain trough or minimum VWF levels of 100-150% for delivery and the immediate postpartum period, followed by levels of 50-100% for 5-10 days after delivery, depending upon the route of delivery. The primary objective is to document the rate of primary postpartum hemorrhage (PPH). The secondary objective is to document further effectiveness outcomes and safety.
For pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels > 50-100%, specific guidance is lacking for delivery planning for how high a VWF level should be achieved. Specifically, guidance is lacking on whether VWF replacement therapy should target a VWF minimum level in the 100-150% range, i.e., a range closer to the 200-250% levels observed in normal pregnancy.
This is a prospective, open-label, cohort study using Wilate VWF replacement therapy, trough or minimum VWF levels of 100-150% will be maintained for delivery in women with VWD whose third trimester VWF levels are \<100%. This group is termed "non-correctors". Women with VWD whose third trimester VWF levels spontaneously rise to >100% will be assigned to the "corrector" group, and these women will not receive VWF replacement therapy. All patients will receive tranexamic acid for 14 days postpartum. Outcome parameters will be assessed for all patients.
The investigators or qualified research personnel will approach all consecutive pregnant VWD patients until 65 non-corrector patients have completed the study protocol, and up to 30 corrector patients have completed the study protocol. Patients with gestational week 34-38 von Willebrand factor activity (VWF:Act) or von Willebrand factor ristocetin cofactor (VWF:RCo), and/or Factor VIII procoagulant activity (FVIII:C) less than 100 percent will be used to assign patients to the non-corrector group. When VWF collagen binding (VWF:CB) laboratory monitoring can be performed, patients with an isolated VWF:CB type 2 defect can also be enrolled.
Rate of primary postpartum hemorrhage, severe postpartum hemorrhage, secondary postpartum hemorrhage will be measured. Safety and secondary laboratory measures will be assessed.
The investigators or qualified research personnel will approach all consecutive pregnant VWD patients. Patients who meet all of the inclusion criteria and none of the exclusion criteria are eligible for this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
or
Written from the patient prepartum, before gestational week 39
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with gestational week 34-38 von Willebrand factor activity, or von Willebrand factor ristocetin cofactor, or Factor VIII procoagulant activity less than 100 percent will be termed non-correctors. When laboratory monitoring can be performed, patients with an isolated von Willebrand factor collagen binding type 2 defect, von Willebrand factor collagen binding less than 100 percent can also be enrolled and determined as a non-corrector.
Other: Use of a postpartum diary and additional blood draws · Drug: VWF replacement therapy with Wilate · Drug: Tranexamic acid
Patients with von Willebrand factor parameter levels greater than or equal to 100 percent self-corrected at gestational weeks 34-38 will be termed correctors.
Drug: Tranexamic acid · Other: Use of a postpartum diary and additional blood draws.
A diary will be used to capture postpartum hemorrhage (PPH), Wilate and tranexamic acid use, other drug use, bleeding episodes, and treatment schedules. Several blood draws additional to what is expected for routine clinical care will also be taken.
This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are \<100% in the third trimester of pregnancy
This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD
A diary will be used to capture postpartum hemorrhage (PPH), tranexamic acid use, other drug use, bleeding episodes, and treatment schedules. Several blood draws additional to what is expected for routine clinical care will also be taken.
rate of primary postpartum hemorrhage (PPH)
defined as the estimated and/or quantified blood loss greater than or equal to 1000 mL within 24 hours postpartum; unplanned transfusion of blood products related to blood loss in the first 24 hours postpartum. As a subset of primary PPH, severe primary PPH is defined as the estimated and/or quantified blood loss greater than or equal to 1500 mL and/or requirement of greater than 2 units packed red blood cells within 24 hours postpartum; primary PPH greater than 1000 mL and evidence of maternal hemodynamic instability (tachycardia, hypotension) and/or end organ damage with no other etiology (oliguria, creatinine greater than 0.8, etc.)
Time frame: within 24 hours postpartum
rate of secondary postpartum hemorrhage (PPH)
excessive blood loss: any transfusions not anticipated in the antepartum birth plan and unrelated to a primary PPH, including number and type of blood component units (blood products, red blood cells, plasma, platelets, cryoprecipitate) transfused within 48 hours after diagnosis and management; any transfusions not anticipated in the antepartum birth plan and unrelated to a primary PPH, including number and type of blood component units (blood products, red blood cells, plasma, platelets, cryoprecipitate) transfused beyond 48 hours after diagnosis and management; change in antepartum hemoglobin; change in pictorial blood assessment chart (PBAC) score; number of patients needing pharmacologic or surgical interventions for bleeding (e.g., use of Bakri balloon, angiographic embolization, B-Lynch sutures, surgical arterial ligation, or hysterectomy for persistent bleeding); iron levels (serum iron, TIBC, and ferritin) 6 weeks postpartum
Time frame: 24 hours to 6 weeks postpartum
occurrence of venous or arterial thrombus
clinically documented venous or arterial thrombus
Time frame: up to 42 days postpartum
occurrence of infusion-related reactions
clinically documented infusion-related reactions
Time frame: up to 42 days postpartum
laboratory assessment of efficacy and VWF replacement
central laboratory assessment of VWF parameters relative to bleeding
Time frame: up to 42 days postpartum
Not enrolling at this site.
Plan to share: No
Started Oct 2019 (actual). Primary completion is estimated for Dec 2026, 86 months after the start.
Of 24 observational studies under von Willebrand Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 97. This study's planned 86 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.